Cephalon
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Cephalon sits in the top decile of US sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count).
Cephalon: 64 sponsored US clinical trials, none currently recruiting.
Cephalon sponsors 64 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 52 completed. 38 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Narcolepsy, with 2 trials.
Top-decile sponsor footprint
Cephalon ranks in the top decile of sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
52 of 64 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
64 total, page 2 of 2
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome
NCT00107809
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236054
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
NCT00228553
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
NCT00236041
SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
NCT00076349
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
NCT00105937
Study of CEP-701 in Treatment of Prostate Cancer
NCT00081601
Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
NCT00078312
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
NCT00079482
Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
NCT00069758
Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD
NCT00214981
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
NCT00233675
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
NCT00040404
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
NCT00293111
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 19 |
| Phase 3 | 35 |
| Phase 4 | 3 |
How the Cephalon archive is shaped
64 indexed studies, none listed as recruiting (0% open); 52 completed (81%).
Phase mix: 38 late (III/IV) vs 25 early (I/II) (later-stage heavy).
Top condition: Narcolepsy (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Cephalon: archived-pipeline peers nationwide
Peers matched on 64 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Cephalon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 64 archived trials
- CooperVision · 64 trials · 3% recruiting
- NRG Oncology · 64 trials · 47% recruiting
- University of Houston · 64 trials · 20% recruiting
- Washington State University · 64 trials · 30% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Cephalon page
64 registered trials is a research-attention snapshot, not an endorsement of Cephalon or any single study.
- None of Cephalon's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Narcolepsy is the condition Cephalon studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Narcolepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Cephalon pipeline card: 64 registered trials from official public datasets.Report a data error.